LifeMap Sciences, a subsidiary of BioTime announced the commercial release of VarElect, a powerful, yet easy-to-use application for prioritizing gene variants resulting from next generation sequencing (“NGS”) experiments.

VarElect rapidly prioritizes gene variants according to their potential association to a disease or phenotype of interest, and can aid in identifying the roles of genes and their variants in biological processes, health, and disease.

VarElect is part of LifeMap Sciences' NGS platform, which also includes GeneAnalytics, an intuitive gene set analysis tool. Both VarElect and GeneAnalytics are part of the GeneCards Plus suite, launched in 2014.

The tools leverage the LifeMap integrated biomedical knowledgebase and discovery platform, which includes GeneCards, the leading human gene database; MalaCards, the human disease database; and LifeMap Discovery, the database of embryonic development, stem cell research, and regenerative medicine. LifeMap holds the exclusive worldwide license to market GeneCards, MalaCards, GeneAlaCart and VarElect from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.

"We believe that VarElect will enable scientists worldwide to cost effectively utilize unprecedented amounts of genetic data from whole exome and genome experiments," stated David Warshawsky, Ph.D., CEO of LifeMap Sciences.